This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:diseases:celiac [07.19.2019] – [Celiac disease] sallieq | home:diseases:celiac [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 8: | Line 8: | ||
- | People with celiac disease react to gluten, which is found in wheat, rye, spelt and barley. Villus atrophy in the small intestine is one of the most significant findings in celiac disease, rendering the patient with a poor absorptive capacity. | + | People with celiac disease react to gluten, which is found in wheat, rye, spelt and barley. Villus atrophy in the small intestine is one of the most significant findings in celiac disease, rendering the patient with a poor absorptive capacity. |
===== Epidemiology ===== | ===== Epidemiology ===== | ||
Line 29: | Line 29: | ||
- | CONCLUSIONS: | + | CONCLUSIONS: |
</ | </ | ||
+ | |||
+ | The emerging data on viral and bacterial microbe-host interactions and their alterations in celiac disease provides a plausible mechanism linking environmental risk and disease development. (({{pmid> | ||
===== Celiac and D metabolite levels ===== | ===== Celiac and D metabolite levels ===== | ||
- | Some patients with celiac disease have low/normal 25D but elevated 1,25D apparently related to celiac. | + | Some patients with celiac disease have low/normal 25D but elevated 1,25D apparently related to celiac. |
- | Our patient had hypocalcemia caused by celiac disease and values for serum 25-hydroxyvitamin D and 1, | + | Our patient had hypocalcemia caused by celiac disease and values for serum 25-hydroxyvitamin D and 1, |
- | Calcium and vitamin D supplement intake may increase arterial stiffness in systemic lupus erythematosus patients. (({{pubmed> | + | Calcium and vitamin D supplement intake may increase arterial stiffness in systemic lupus erythematosus patients. (({{pmid> |
- | (({{pubmed> | + | (({{pmid> |
===== Evidence of infectious cause ===== | ===== Evidence of infectious cause ===== | ||
- | < | + | < |
</ | </ | ||
< | < | ||
- | Sabayan B, Foroughinia F, Imanieh MH (({{pubmed> | + | Sabayan B, Foroughinia F, Imanieh MH (({{pmid> |
- | Specific duodenal and faecal bacterial groups are associated with paediatric celiac disease.(({{pubmed> | + | Specific duodenal and faecal bacterial groups are associated with paediatric celiac disease.(({{pmid> |
- | Lymphocytic gastritis and celiac disease in indian children: evidence of a positive relation.(({{pubmed> | + | Lymphocytic gastritis and celiac disease in indian children: evidence of a positive relation.(({{pmid> |
- | Autoantibodies involved in celiac disease are not specific, as infection may increase levels of anti-transglutaminase antibodies. These antibodies are not detectable once the infection is gone.(({{pubmed> | + | Autoantibodies involved in celiac disease are not specific, as infection may increase levels of anti-transglutaminase antibodies. These antibodies are not detectable once the infection is gone.(({{pmid> |
==== recent research ==== | ==== recent research ==== | ||
Line 61: | Line 63: | ||
Could a common virus trigger coeliac disease in some children? | Could a common virus trigger coeliac disease in some children? | ||
- | [[http:// | + | [[https:// |
- | (({{pubmed> | + | (({{pmid> |
- | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | + | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. |
+ | |||
+ | In 2015 I saw that 6 individuals in the USA were suing maker of Benicar. (// | ||
+ | |||
+ | Gluten in " | ||
- | In 2015 I read that 6 individuals in the USA are currently suing maker of Benicar. Somewhere I saw that 1.9 million individuals are currently taking Olmesartan Medoxomil. | ||
2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. | 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. | ||
- | (({{pubmed> | + | (({{pmid> |
+ | |||
+ | Research associated with J Tye-Din | ||
+ | |||
{{tag> | {{tag> | ||
Line 76: | Line 85: | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
Line 118: | Line 128: | ||
Romain Bouziat1, | Romain Bouziat1, | ||
as link will likely break (news media) | as link will likely break (news media) | ||
- | ===== References ===== | + | ===== References =====</ |